(1)
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
19.01.2021 / 15:00
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplus
TM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
Secarna s partner Lipigon has selected an LNAplus
TM ASO candidate targeting ANGPTL4, called
Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development
High levels of plasma lipids triglycerides are associated with a plethora of lipid-related diseases with yet unmet clinical treatment needs